MA49652A - Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation - Google Patents

Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation

Info

Publication number
MA49652A
MA49652A MA049652A MA49652A MA49652A MA 49652 A MA49652 A MA 49652A MA 049652 A MA049652 A MA 049652A MA 49652 A MA49652 A MA 49652A MA 49652 A MA49652 A MA 49652A
Authority
MA
Morocco
Prior art keywords
antigen
fields
methods
type iii
binding regions
Prior art date
Application number
MA049652A
Other languages
English (en)
Inventor
Chichi Huang
John Lee
Jill Mooney
Michael Naso
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA49652A publication Critical patent/MA49652A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA049652A 2017-07-17 2018-07-17 Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation MA49652A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533341P 2017-07-17 2017-07-17
US201862625576P 2018-02-02 2018-02-02

Publications (1)

Publication Number Publication Date
MA49652A true MA49652A (fr) 2020-05-27

Family

ID=65000212

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049652A MA49652A (fr) 2017-07-17 2018-07-17 Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation

Country Status (11)

Country Link
US (2) US11161897B2 (fr)
EP (1) EP3655026A4 (fr)
JP (1) JP7280238B2 (fr)
KR (1) KR20200028447A (fr)
CN (1) CN111093696B (fr)
AU (1) AU2018304173A1 (fr)
CA (1) CA3070100A1 (fr)
IL (1) IL271982A (fr)
MA (1) MA49652A (fr)
MX (1) MX2020000595A (fr)
WO (1) WO2019018402A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020322221A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)
WO2021076546A1 (fr) * 2019-10-14 2021-04-22 Aro Biotherapeutics Company Domaines de type iii de fibronectine de liaison à cd137
WO2021087356A1 (fr) * 2019-11-01 2021-05-06 The Trustees Of The University Of Pennsylvania Récepteurs d'antigènes chimériques ciblant la fibronectine (car)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
IL151287A0 (en) 2000-02-24 2003-04-10 Xcyte Therapies Inc A method for stimulation and concentrating cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
FR2844519A1 (fr) * 2002-09-17 2004-03-19 Bio Merieux Proteine recombinante chimerique et diagnostic in vitro
US8703134B2 (en) * 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
EP1711527A4 (fr) * 2003-12-15 2008-09-03 Dendreon Corp Anticorps specifiques de hla-dr, compositions et methodes associees
EP2562259B1 (fr) 2004-12-21 2016-07-06 Monsanto Technology LLC Plantes transgéniques dotées de traits agronomiques améliorés
EP1973576B1 (fr) 2005-11-28 2019-05-15 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
ES2566602T3 (es) * 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
RU2603272C2 (ru) * 2010-04-30 2016-11-27 Янссен Байотек, Инк. Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения
WO2012059562A1 (fr) * 2010-11-03 2012-05-10 Argen-X-Bv Combinaisons d'anticorps c-met
BR112013013723A2 (pt) * 2010-12-02 2019-09-24 The Washington University composições e métodos para tratar sintomas associados à plca amilóide
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
MX370265B (es) 2012-05-25 2019-12-09 Cellectis Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
KR102141259B1 (ko) 2012-09-04 2020-08-05 셀렉티스 멀티―체인 키메라 항원 수용체 및 그것의 용도들
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP3689370A1 (fr) 2012-12-21 2020-08-05 Aveo Pharmaceuticals Inc. Anticorps anti-gdf15
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
WO2014160627A1 (fr) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides anti-cd276, protéines, et récepteurs d'antigènes chimériques
FI2997141T3 (fi) 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
CN105378067A (zh) 2013-05-13 2016-03-02 塞勒克提斯公司 工程化用于免疫治疗的高活性t细胞的方法
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
PL3092251T3 (pl) 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
DK3129470T3 (da) * 2014-04-07 2021-07-05 Novartis Ag Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
KR20240090732A (ko) * 2015-02-19 2024-06-21 컴퓨젠 엘티디. 항-pvrig 항체 및 사용 방법
HUE059218T2 (hu) * 2015-04-08 2022-11-28 Novartis Ag CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
EP3292222A4 (fr) * 2015-05-06 2018-10-17 Janssen Biotech, Inc. Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostate
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US10688178B2 (en) * 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
EP3350224B1 (fr) * 2015-09-20 2024-06-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Anticorps monoclonaux spécifiques du récepteur de facteur de croissance des fibroblastes 4 (fgfr4) et leurs procédés d'utilisation
JP6914956B2 (ja) * 2015-11-24 2021-08-04 ビョンディス・ビー．ブイ．Ｂｙｏｎｄｉｓ Ｂ．Ｖ． 抗５ｔ４抗体および抗体−薬物コンジュゲート
US20200270365A1 (en) * 2016-01-05 2020-08-27 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
WO2018052828A1 (fr) * 2016-09-14 2018-03-22 Janssen Biotech, Inc. Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
WO2019118475A1 (fr) * 2017-12-13 2019-06-20 Janssen Biotech, Inc. Lymphocytes car-t immortalisés génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et de la bêta 2-microglobuline

Also Published As

Publication number Publication date
WO2019018402A3 (fr) 2019-02-28
US11161897B2 (en) 2021-11-02
JP2020530766A (ja) 2020-10-29
MX2020000595A (es) 2020-09-10
US20190016789A1 (en) 2019-01-17
CN111093696B (zh) 2023-10-27
WO2019018402A2 (fr) 2019-01-24
CN111093696A (zh) 2020-05-01
EP3655026A4 (fr) 2021-07-28
JP7280238B2 (ja) 2023-05-23
EP3655026A2 (fr) 2020-05-27
CA3070100A1 (fr) 2019-01-24
KR20200028447A (ko) 2020-03-16
IL271982A (en) 2020-02-27
US20220127343A1 (en) 2022-04-28
AU2018304173A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA56165A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA44490A (fr) Adhésifs biocompatibles et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA48852A (fr) Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42302A (fr) Lactames bicycliques et leurs méthodes d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA43025A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation